Genomic landscape of Waldenström’s macroglobulinemia

Steven P. Treon¹,², Zachary R. Hunter¹,², Andrew R. Branagan²,³, Jorge J. Castillo¹,²

¹Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, United States; ²Department of Medicine, Harvard Medical School, Boston, United States; ³Division of Hematology-Oncology, Massachusetts General Hospital, Boston, United States

Take home messages

- Next-generation sequencing has revealed recurring somatic mutations in Waldenström’s Macroglobulinemia that include MYD88 (95%–97%), CXCR4 (30%–40%), ARID1A (17%) and CD79B (8%–15%).
- Deletions involving chromosome 6q are common in MYD88 mutated patients, and include genes that modulate NFKB, BCL2, BTK, and apoptosis.
- Wild-type MYD88 Waldenström’s Macroglobulinemia (WM) patients show an increased risk of transformation and death, and exhibit many mutations found in diffuse large B-cell lymphoma.
- Response to the BTK inhibitor ibrutinib is impacted by both MYD88 and CXCR4 mutation status in WM.

Introduction

Whole genome sequencing has identified recurring somatic mutations in MYD88, CXCR4, ARID1A, and CD79, along with copy number alterations including those in chromosome 6q that impact regulatory genes affecting NFKB, BTK, BCL2, and apoptosis. Herein, we discuss the genomic landscape of Waldenström’s Macroglobulinemia (WM), and the impact of underlying genomics on disease presentation, treatment outcome, and overall survival impact.

Current state of art

Mutations in MYD88

A recurring somatic mutation in MYD88 (MYD88 L265P) was identified in 91% of WM patients by paired tumor/normal whole genome sequencing. By more sensitive allele-specific PCR testing, MYD88 L265P was expressed in 93% to 97% of WM patients. Non-L265P MYD88 mutations have also been identified in 1% to 2% of WM patients. MYD88 mutations are also detectable in 50% to 80% of cases of IgM Monoclonal Gammapathy of Unknown Significance (MGUS), suggesting an early oncogenic role for WM pathogenesis.²,⁴

Nine different mutations have been reported in CXCR4 with the C-terminal domain being the most common. Mutations in CXCR4 are present in up to 40% of WM patients when isolated bone marrow CD19-selected cells are used for sequencing, and while they almost always occur with MYD88 mutations, some patients with wild-type MYD88 can also express these mutations.¹,⁷CXCR4 mutations are essentially unique to WM, with only rare reports in marginal zone lymphoma (MZL) and ABC diffuse large B-cell lymphoma (DLBCL) cases.

Unlike MYD88, CXCR4 mutant clonality is highly variable. Multiple CXCR4 mutations can also exist within individual patients that occur in separate clones or are present as compound heterozygous events.¹¹ The subclonal nature of CXCR4 mutations relative to MYD88 suggests that these mutations occur after MYD88, though this is likely to be an early event in WM pathogenesis given their detection in IgM MGUS patients. Clonal 6q deletions which are found in 40% to 50% of WM patients, appear exclusive of CXCR4.¹²

The authors report no conflicts of interest.

References

1. Treon SP, Hunter ZR, Branagan AR, Castillo JJ. Genomic Landscape of Waldenström’s Macroglobulinemia. HemaSphere, 2019;3:S2, http://dx.doi.org/10.1097/HS9.0000000000000228

Version: 03202019
Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HemaSphere (2019) 3:S2
Received: 1 February 2019 / Received in final form: 20 March 2019 / Accepted: 21 March 2019
Citation: Treon SP, Hunter ZR, Branagan AR, Castillo JJ. Genomic Landscape of Waldenström’s Macroglobulinemia. HemaSphere, 2019;3:S2, http://dx.doi.org/10.1097/HS9.0000000000000228

Powered by EHA
Patients with CXCR4 mutations present with a significantly lower rate of adenopathy, and those with CXCR4 nonsense mutations have increased bone marrow disease, serum IgM levels, and symptomatic hyperviscosity. Despite differences in clinical presentation, CXCR4 mutations do not appear to adversely impact overall survival in WM. In vitro modeling of WM cells transduced with mutated CXCR4 showed increased drug resistance in the presence of CXCL12 to multiple therapeutics including bendamustine, fludarabine, bortezomib, idelalisib, and ibrutinib. Other recurring mutations

Somatic mutations in ARID1A are present in 17% of WM patients, nonsense and frameshift variants. Patients with ARID1A and MYD88 L265P mutations showed greater bone marrow disease involvement, and lower hemoglobin and platelet count. ARID1A and its frequently deleted homolog ARID1B (discussed below) are on chromosome 6q. Both serve as chromatin remodeling genes (CRG) thereby modulating gene regulation. While still poorly understood, ARID1A can modulate TP53, and is thought to act as an epigenetic tumor suppressor in ovarian cancer. CD79A and CD79B can be found in 8% to 12% of WM patients. Both are components of the B-cell receptor (BCR) pathway, and can form heterodimers with each other. The CD79A/B heterodimer associates with the immunoglobulin heavy chain required for cell surface expression of BCR, and BCR induced signaling. Activating mutations in the immunotyrosine-based activation motif (ITAM) of CD79A and CD79B have been reported in ABC DLBCL, and trigger SYK, PLCγ2, and BTK.

Mutations in MYD88 wild-type WM

A small number of WM patients (5%) lack mutations in MYD88, and their disease course is marked by increased risk of disease transformation and shorter overall survival. Moreover, these patients show little activity to ibrutinib. These findings point to fundamental differences in underlying genomics. Whole exome sequencing identified somatic mutations in MYD88 wild-type WM patients that are predicted to trigger NFKB (BTL1XR1, PTPN13, MALT1, BCL10, NFKB1, NFKB2, NFKBIB, NFKBH2, and UDR11F), impart epigenomic dysregulation (KMT2D, KMT2C, KDM6A), or impair DNA damage repair (TP53, ATM, and TRRAP). Predicted NFKB activating mutations were downstream of BTK, and many overlapped with somatic mutations found in DLBCL.

Figure 1. Mutated MYD88 related signaling in Waldenstrom’s Macroglobulinemia. Mutated MYD88 transactivates NFKB through divergent pathways that include IRAK1/IRAK4 and BTK. Mutated MYD88 also triggers transcription and activation of the SRC family member HCK. Activated HCK can then trigger BTK, AKT, and ERK1/2 mediated pro-growth and survival signaling in WM cells. Copy number abnormalities including loss of 6q are common in WM patients, and impact regulators of MYD88 signaling including inhibitor of BTK (IBTK), TNFAIP3, and HIVEP2. ibrutinib can target BTK and HCK.
Copy number alterations

Copy number alterations are common in MYD88 mutated WM patients, and involve both chromosome 6q, and non-chromosome 6q regions.1 In chromosome 6q, loss of genes that modulate NFkB activity (TNFAIP3, HIVEP2), BCL2 (BCLAF1), apoptosis (FOXO3), BTK (IBTK), plasma cell differentiation (PRDM1) and ARID1B occur.12 Non-chromosome 6q genes that are commonly deleted include ETV6, a transcription repressor; BTG1, that often is deleted in DLBCL, and associated with glucocorticoid resistance in acute lymphocytic leukemia; as well as LYN, a kinase that regulates BCR signaling.13 PRDM2 and TOP1 that participate in TP53-related signaling are also deleted in many WM patients. In contrast to MYD88 mutated WM, recurring copy number alterations are rare in MYD88 wild-type WM, including loss of chromosome 6q.10

Clinical perspectives

At present, MYD88 mutational status can help in the diagnosis, and prognosis of WM patients.1 Those lacking mutated MYD88 by allele-specific PCR analysis for the L265P mutation should be investigated for non-L265P mutations by Sanger sequencing. Patients with suspected WM and wild-type MYD88 should be excluded for other diagnoses including IGM myeloma.13 Patients wild-type WM show increased incidence of disease transformation, and can be more closely monitored.13 MYD88 mutation status can also serve as an important predictive marker for use of ibrutinib (and possibly other BTK-inhibitors) in WM patients. Patients with wild-type MYD88 are not very responsive to ibrutinib, and therefore its use should be reserved for those WM patients with mutated MYD88.3 CXCR4 mutations are associated with delayed response, lower rates of deeper responses including very good partial response attainment, and shorter progression-free survival.16 The former is important to consider in patients in whom rapid responses are required for disease control.13

Future perspectives

The discovery of recurring somatic mutations in MYD88, CXCR4, ARID1A, and CD79B mutations in WM offers important new insights into the pathogenesis, prognostication and therapeutic development for WM. The latter includes agents that target key pro-survival signaling in the MYD88 pathways including inhibitors of BTK, IRAK, and HCK. The BTK inhibitors ibrutinib, acalabrutinib and zanubrutinib have shown remarkable activity in WM, and ibrutinib is now approved in the US and Europe, as well as other countries for the treatment of symptomatic WM.17,18,19 Selective inhibitors targeting IRAK and HCK are also in pre-clinical and/or early stage clinical development. CXCR4 represents an important target in WM, and a clinical trial assessing the impact of the CXCR4 inhibitor uboclopinib with ibrutinib in CXCR4 mutated WM patients (NCT03225716) is ongoing with encouraging early findings.20 Targeting CD79B signaling through use of SYK inhibitors also appears feasible based on preclinical studies, which show the potential for synergistic interactions with ibrutinib, and may be suitable for those patients with CD79B mutations.7 The genomic findings, therefore, lay the foundation for targeted drug development, and the potential for a personalized medicine approach to WM.

References

1. Hunter ZR, Yang G, Xu L, et al. Genomics, signaling, and treatment of waldenstrom macroglobulinaemia. J Clin Oncol. 2017; 35:994–1001.

2. Treon SP, Xu L, Yang G, et al. MYD88 L263P somatic mutation in Waldenström’s macroglobulinaemia. N Engl J Med. 2012;367: 826–833.

3. Treon SP, Xu L, Hunter ZR. MYD88 mutations and response to ibrutinib in Waldenström’s Macroglobulinemia. N Engl J Med. 2015;373:594–596.

4. Jiménez C, Sebastián E, Del Carmen Chillón M, et al. MYD88 L263P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia. Leukemia. 2013;27:1722–1728.

5. Poulain S, Roumier C, Decambron A, et al. MYD88 L263P mutation in Waldenström’s macroglobulinemia. Blood. 2013;121:4504–4511.

6. Varettoni M, Zibellini S, Arcaini L, et al. MYD88 (L263P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood. 2013;122:2284–2285.

7. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–119.

8. Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L263P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinaemia. Blood. 2013;88:1222–1223.

9. Yang G, Buhrlage S, Tan L, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016;127:3237–3252.

10. Hunter ZR, Xu L, Tsakmaklis N, et al. Insights into the genomic landscape of MYD88 wild-type Waldenström’s Macroglobulinemia. Blood Adv. 2018;13:2937–2946.

11. Xu L, Hunter ZR, Tsakmaklis N, et al. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia. Br J Haematol. 2016;172:735–744.

12. Guerrera ML, Tsakmaklis N, Xu L, et al. MYD88 mutated and wild-type Waldenström Macroglobulinemia: Characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica. 2018;103:e408–e411.

13. Treon SP, Gustine J, Xu L, et al. MYD88 wild-type Waldenström Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018;180:374–380.

14. Cao Y, Hunter ZR, Liu X, et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88 (L263P)-directed survival signalling in Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015;168:701–707.

15. Roxo AM, Sacco A, Jimenez C, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123:4120–4131.

16. Treon SP, Meid K, Gustine J, et al. Ibrutinib shows prolonged progression-free survival in symptomatic, previously treated patients with MYD88 mutated Waldenström’s Macroglobulinemia: long term follow-up of the pivotal trial (NCT01614821). Proc Eur Soc Hematol. 2018;Abstract PS1185.

17. Dimpoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s Macroglobulinemia. N Engl J Med. 2018;378:2399–2410.

18. Owen R, McCarthy H, Rule S, et al. Acalabrutinib in patients with Waldenström Macroglobulinemia. In Proceedings of the 23rd Congress of the European Hematopathology Association 2018, Stockholm, Sweden (abstract S853).

19. Trotman J, Tam CS, Marthon P, et al. Improved depth of response with increased follow-up for patients with Waldenström
Macroglobulinemia treated with Bruton’s Tyrosine Kinase inhibitor zanubrutinib. In Proceedings of the 23rd Congress of the European Hematology Association 2018, Stockholm, Sweden (abstract PS1186).

20. Treon SP, Meid K, Keezer A, Xu L, Tsakmaklis N, Kofides A, Demos M, Yang G, Hunter ZR, Dubeau T, Castillo J. Clinical Trials in Progress: Phase I/II clinical trial of CXCR4 inhibitor ulocuplomab plus ibrutinib in symptomatic Waldenstrom’s Macroglobuloinemia with CXCR4 WHIM mutations. In Proceedings of the 10th International Workshop on Waldenström’s Macroglobulinemia, October 11–13, 2018, New York City, NY, USA.

21. Munshi M, Chen J, Liu X, et al. MYD88 triggered SYK activation promotes BCR cross-talk, and identifies SYK as a novel therapeutic target of mutated MYD88 signaling. In Proceedings of the American Society of Hematology 2018, San Diego, CA (abstract 4116).